Renal Cell Carcinoma
Toni K. Choueiri, MD, Guest Editor Since December 2005 and as of August 2011, the date of this issue, six “targeted” drugs have been approved in metastatic renal cell carcinoma…
HEMATOLOGY
Systemic Mastocytosis
An unusual disease, mastocytosis challenges the pathologist with a variety of morphologic appearances and heterogeneous clinical presentations ranging from skin manifestations (pruritus, urticaria, dermatographism) to systemic signs and symptoms indicative…
Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era
In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established…
Diagnosis of Myelodysplastic Syndromes in Cytopenic Patients
Sustained clinical cytopenia is a frequent laboratory finding in ambulatory and hospitalized patients. For pathologists and hematopathologists who examine the bone marrow (BM), a diagnosis of cytopenia secondary to an…
Portal Vein Thrombosis and Budd–Chiari Syndrome
Venous thrombosis results from the convergence of vessel wall injury and/or venous stasis, known as local triggering factors, and the occurrence of acquired and/or inherited thrombophilia, also known as systemic…
Selection of Therapy: Rational Decisions Based on Molecular Events
This article reviews to what extent molecular data can be used to rationalize therapeutic choices in the treatment of chronic myeloid leukemia. Two categories of data are discussed: markers that…
Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment
Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However,…
BCR-ABL Mutations in Chronic Myeloid Leukemia
The advent of imatinib has been a major breakthrough in chronic myeloid leukemia (CML) treatment. A few patients treated with imatinib are either refractory to imatinib or eventually relapse. Resistance…
Hurdles Toward a Cure for CML: The CML Stem Cell
Chronic myeloid leukemia (CML) is the first cancer in which a genetic alteration was proven to be of pathogenic significance and is considered a disease model for oncogene addiction, targeted…
The Biology of Chronic Myelogenous Leukemia Progression: Who, What, Where, and Why?
Before the days of transplantation and tyrosine kinase inhibitor therapy, all cases of chronic myelogenous leukemia would inevitably proceed from chronic phase through accelerated and blast crisis, implying that there…
